MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262. PMID:25651787
   PubMed Web of Science ®Google Scholar
• Yeo B, Turner NC, Jones A. An update on the medical management of breast cancer. BMJ. 2014;348:g3608. doi:10.1136/bmj.g3608. PMID:24912480
   PubMed Web of Science ®Google Scholar
• Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–13. doi:10.1038/nrd1031. PMID:12612646
   PubMed Web of Science ®Google Scholar
• Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25:270–75. doi:10.1038/bjc.1971.33. PMID:5115829
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84. doi:10.1016/S0140-6736(11)60993-8. PMID:21802721
   PubMed Web of Science ®Google Scholar
• Nass N, Kalinski T. Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol Res Pract. 2015;211:189–97. doi:10.1016/j.prp.2015.01.004. PMID:25666016
   PubMed Web of Science ®Google Scholar
• Dixon J.M. Endocrine resistance in Breast cancer. N J Sci. 2014;2014:1–27. doi:org/10.1155/2014/390618.
   Google Scholar
• Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol. 2005;19:1740–51. doi:10.1210/me.2004-0011. PMID:15746193
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573–83. doi:10.1038/nrclinonc.2015.117. PMID:26122181
   PubMed Web of Science ®Google Scholar
• Cui J, Yang Y, Li H, Leng Y, Qian K, Huang Q, Zhang C, Lu Z, Chen J, Sun T, et al. MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene. 2015;34:3895–907. doi:10.1038/onc.2014.430. PMID:25531331
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1–222. doi:10.1080/15548627.2015.1100356. PMID:26799652
   PubMed Web of Science ®Google Scholar
• Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, Browning D, Rawson J, Smith SB, Barrett JT, et al. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther. 2008;7:2977–87. doi:10.1158/1535-7163.MCT-08-0447. PMID:18790778
   PubMed Web of Science ®Google Scholar
• Cook KL, Shajahan AN, Wärri A, Jin L, Hilakivi-Clarke LA, Clarke R. Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res. 2012;72:3337–49. doi:10.1158/0008-5472.CAN-12-0269. PMID:22752300
   PubMed Web of Science ®Google Scholar
• Nagelkerke A, Sieuwerts AM, Bussink J, Sweep FC, Look MP, Foekens JA, Martens JW, Span PN. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. Endocr Relat Cancer. 2014;21:101–12. doi:10.1530/ERC-13-0183. PMID:24434718
   PubMed Web of Science ®Google Scholar
• Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, Gorski SM. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat. 2008;112:389–403. doi:10.1007/s10549-007-9873-4. PMID:18172760
   PubMed Web of Science ®Google Scholar
• Cook KL, Wärri A, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A, Clarke R. Chloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res. 2014;20:3222–32. doi:10.1158/1078-0432.CCR-13-3227. PMID:24928945
   PubMed Web of Science ®Google Scholar
• Toh Y, Nicolson GL. Properties and clinical relevance of MTA1 protein in human cancer. Cancer Metastasis Rev. 2014;33:891–900. doi:10.1007/s10555-014-9516-2. PMID:25359582
   PubMed Web of Science ®Google Scholar
• Sen N, Gui B, Kumar R. Role of MTA1 in cancer progression and metastasis. Cancer Metastasis Rev. 2014;33:879–89. doi:10.1007/s10555-014-9515-3. PMID:25344802
   PubMed Web of Science ®Google Scholar
• Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC, O'Connell P. Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Res. 2001;61:3578–80. PMID:11325822
   PubMed Web of Science ®Google Scholar
• Jang KS, Paik SS, Chung H, Oh YH, Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci. 2006;97:374–79. doi:10.1111/j.1349-7006.2006.00186.x. PMID:16630134
   PubMed Web of Science ®Google Scholar
• Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell P. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006;95:7–12. doi:10.1007/s10549-005-9016-8. PMID:16244788
   PubMed Web of Science ®Google Scholar
• Cheng CW, Liu YF, Yu JC, Wang HW, Ding SL, Hsiung CN, Hsu HM, Shieh JC, Wu PE, Shen CY. Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. Ann Surg Oncol. 2012;19:4129–39. doi:10.1245/s10434-012-2541-x. PMID:22864797
   PubMed Web of Science ®Google Scholar
• Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol. 2001;3:30–7. doi:10.1038/35050532. PMID:11146623
   PubMed Web of Science ®Google Scholar
• Singh RR, Barnes CJ, Talukder AH, Fuqua SA, Kumar R. Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein. Cancer Res. 2005;65:10594–601. doi:10.1158/0008-5472.CAN-05-2268. PMID:16288053
   PubMed Web of Science ®Google Scholar
• Gururaj AE, Holm C, Landberg G, Kumar R. Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer. Cell Cycle. 2006;5:1407–10. doi:10.4161/cc.5.13.2924. PMID:16855396
   PubMed Web of Science ®Google Scholar
• Briand P, Lykkesfeldt AE. Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res. 1984;44:1114–19. PMID:6362856
   PubMed Web of Science ®Google Scholar
• Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Lænkholm AV, Bak M, Lykkesfeldt AE, Yde CW. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene. 2015;34:4199–210. doi:10.1038/onc.2014.351. PMID:25362855
   PubMed Web of Science ®Google Scholar
• Marin TL, Gongol B, Martin M, King SJ, Smith L, Johnson DA, et al. Identification of AMP-activated protein kinase targets by a consensus sequence search of the proteome. BMC Syst Biol. 2015;9:13. doi:10.1186/s12918-015-0156-0. PMID:25890336
   PubMed Web of Science ®Google Scholar
• Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res. 2008;14:1744–52. doi:10.1158/1078-0432.CCR-07-1833. PMID:18347175
   PubMed Web of Science ®Google Scholar
• Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607–16. doi:10.1016/j.ccr.2004.05.015. PMID:15193263
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, et al. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat. 2009;116:303–09. doi:10.1007/s10549-008-0183-2. PMID:18821012
   PubMed Web of Science ®Google Scholar
• Daurio NA, Tuttle SW, Worth AJ, Song EY, Davis JM, Snyder NW, Blair IA, Koumenis C. AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment. Cancer Res. 2016;76:3295–306. doi:10.1158/0008-5472.CAN-15-2197. PMID:27020861
   PubMed Web of Science ®Google Scholar
• Kang HJ, Lee MH, Kang HL, Kim SH, Ahn JR, Na H, Na TY, Kim YN, Seong JK, Lee MO. Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis-associated protein 1. Cancer Res. 2014;74:1484–94. doi:10.1158/0008-5472.CAN-13-2020. PMID:24413532
   PubMedGoogle Scholar
• Mishra SK, Mazumdar A, Vadlamudi RK, Li F, Wang RA, Yu W, Jordan VC, Santen RJ, Kumar R. MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem. 2003;278:19209–19. doi:10.1074/jbc.M301968200. PMID:12639951
   PubMed Web of Science ®Google Scholar
• Talukder AH, Gururaj A, Mishra SK, Vadlamudi RK, Kumar R. Metastasis-associated protein 1 interacts with NRIF3, an estrogen-inducible nuclear receptor coregulator. Mol Cell Biol. 2004;24:6581–91. doi:10.1128/MCB.24.15.6581-6591.2004. PMID:15254226
   PubMed Web of Science ®Google Scholar
• Khaleque MA, Bharti A, Gong J, Gray PJ, Sachdev V, Ciocca DR, Stati A, Fanelli M, Calderwood SK. Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1. Oncogene. 2008;27:1886–93. doi:10.1038/sj.onc.1210834. PMID:17922035
   PubMed Web of Science ®Google Scholar
• Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene. 2015;34:1919–27. doi:10.1038/onc.2014.138. PMID:24882577
   PubMed Web of Science ®Google Scholar
• Cook KL, Clarke PA, Parmar J, Hu R, Schwartz-Roberts JL, Abu-Asab M, Wärri A, Baumann WT, Clarke R. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death. FASEB J. 2014;28:3891–905. doi:10.1096/fj.13-247353. PMID:24858277
   PubMed Web of Science ®Google Scholar
• Hsieh DJ, Kuo WW, Lai YP, Shibu MA, Shen CY, Pai P, Yeh YL, Lin JY, Viswanadha VP, Huang CY. 17β-Estradiol and/or Estrogen Receptor β Attenuate the Autophagic and Apoptotic Effects Induced by Prolonged Hypoxia Through HIF-1α-Mediated BNIP3 and IGFBP-3 Signaling Blockage. Cell Physiol Biochem. 2015;36:274–84. doi:10.1159/000374070. PMID:25967966
   PubMed Web of Science ®Google Scholar
• Newby JC, Johnston SR, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 1997;3:1643–51. PMID:9815855
   PubMed Web of Science ®Google Scholar
• Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 1999;79:1220–26. doi:10.1038/sj.bjc.6690196. PMID:10098763
   PubMed Web of Science ®Google Scholar
• Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011;17:1147–59. doi:10.1158/1078-0432.CCR-10-1869. PMID:21220480
   PubMed Web of Science ®Google Scholar
• Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104:1828–35. doi:10.1038/bjc.2011.156. PMID:21559012
   PubMed Web of Science ®Google Scholar
• Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A. 2012;109:6561–65. doi:10.1073/pnas.1204429109. PMID:22493260
   PubMed Web of Science ®Google Scholar
• Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, et al. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One. 2013;8:e76503. doi:10.1371/journal.pone.0076503. PMID:24146879
   PubMed Web of Science ®Google Scholar
• Stocchi V, Cucchiarini L, Magnani M, Chiarantini L, Palma P, Crescentini G. Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells. Anal Biochem. 1985;146:118–24. doi:10.1016/0003-2697(85)90405-1. PMID:3993925
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137. doi:10.1186/gb-2008-9-9-r137. PMID:18798982
   PubMed Web of Science ®Google Scholar
• Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29:24–6. doi:10.1038/nbt.1754. PMID:21221095
   PubMed Web of Science ®Google Scholar
• Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009;37:W305–11. doi:10.1093/nar/gkp427. PMID:19465376
   PubMed Web of Science ®Google Scholar